Sapna S. Tejwani firstname.lastname@example.org
University of Pennsylvania, Philadelphia, PA B.S.E., Magna Cum Laude, Finance, 2004 B.A.S., Magna Cum Laude, Biomedical Science, 2004
Jared H. Teo
University of California at San Diego, La Jolla, CA
B.S., Bioengineering, 2004
Laura G. Thompson laura.th
Dartmouth College, Hanover, NH B.A., Economics, 2004
An opportunity to work in health care-focused private equity or business development.
J.P. Morgan Chase, New York, NY Summer Associate – Healthcare Investment Banking, Summer 2010
Supported M&A ($730M sale of medical research company) and financing transactions. Conducted valuation assessments of medtech companies using DCF, comparable company, precedent transaction, leveraged buy-out, and sum-of-the- parts approaches. Created comprehen- sive merger model to evaluate potential specialty pharma transactions under various offer price, synergy, and financing terms.
The Monitor Group, New York, NY Case Team Leader, 2005-2009
Led teams of 4-10 to provide strategic transaction advice (e.g., M&A, port - folio rationalization, JVs, corporate venturing) to corporate executives. Advised CEO and Board of biotech on long-term strategy; assessed company’s implied value under various regulatory and commercial scenarios; determined merits, valuation, and optimal timing for M&A and in-licensing. Created M&A roadmap for Fortune 100 medtech to enable novel drug-device combinations; identified attractive cardio, neuro, and endo-vascular technologies resulting in $1Bn+ acquisition. Designed launch- plan for premier biotech’s RA drug; built epidemiological model and customer segmentation; worked with health-economics group to demon- strate drug’s cost-efficacy to payers.
An opportunity in health care business development, private equity, or venture capital.
Bank of America Merrill Lynch, San Francisco, CA
Summer Associate, Healthcare Group, Summer 2010
Performed valuation and M&A analy- sis and prepared company-specific presentations detailing financing alternatives, strategic acquisition opportunities and industry and capital market landscapes for companies within the health care sector.
Phoenix DeVentures, Morgan Hill, CA Project Manager, 2008-2009 Managed a team of engineers through the design and development of neurovascular and orthopedic products for clients and interacted closely with entrepreneurs and start-up companies to assess commercial/technical feasibility of novel product ideas.
Ev3 (Acquired by Covidien) R&D Engineer III/Project Manager, 2005-2008
Managed interdepartmental group of 15 through the commercialization of 2 medical devices (SilverHawk EXL and LX-M) from concept to market launch as youngest Project Manager in company history. Researched existing and potential competitors; identified product weakness and secured pivotal funding to create high performance atherectomy catheter.
CryoCor (Acquired by Boston Scientific) Associate R&D Engineer, 2004-2005 Created detailed engineering models to evaluate potential design improve- ments in next generation products.
An opportunity to invest in health care companies at a private equity firm.
Northgate Capital Partners, Danville, CA Summer Analyst Intern, Summer 2010 Evaluated funds for investment poten- tial, analyzing strategy, management team, track record and sector. Monitored direct investments and completed valuation models and write-ups for annual audit. Assisted in creating templates and refining processes for future fund evaluations.
W Capital Partners, New York, NY Associate, 2006-2009
Served as one of nine investment pro- fessionals managing $1B of committed capital and more than 200 portfolio companies. Evaluated investments in the secondary market through detailed analysis of capital structure, growth potential, risks, and expected exit values. Managed portfolio compa- nies by working directly with CFOs, CEOs and boards to track progress, make strategic decisions, and evaluate and complete follow-on investments using financial models, drafting term sheets, and negotiating terms.
Banc of America Securities, New York, NY Analyst, 2004-2006
Evaluated companies and transactions by applying the following methodolo- gies: discounted cash flow, pro-forma merger, leveraged buyout, comparable company and precedent transaction analyses. Prepared board and senior management presentations, offering memoranda, fairness opinions, and roadshow presentations.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40